GBA1变异帕金森病患者脑深部电刺激的长期运动与认知结局
这项多中心回顾性对照研究纳入615例帕金森病患者,比较DBS治疗的GBA1携带者与非携带者及未手术GBA1携带者的长期结局。结果显示DBS两组运动症状均显著改善,GBA1携带者痴呆发生率高于非携带者,但手术与未手术GBA1组相似,提示认知下降由基因型而非DBS驱动。
要点
- DBS对GBA1变异帕金森病患者运动症状有长期获益。
- GBA1携带者痴呆风险高于非携带者,但与是否手术无关。
- 证据等级Class III,支持DBS不加重GBA1相关帕金森病认知功能。
核心结论
- DBS是GBA1变异帕金森病的有效治疗选择,提供长期运动症状和生活质量获益。
- GBA1携带者认知下降加速由基因型驱动,而非DBS本身。
研究设计与样本
- 多中心回顾性对照研究,纳入615例参与者:430例DBS非GBA帕金森病、109例DBS-GBA帕金森病、76例未手术GBA帕金森病。
- 基线及术后1、3、5年收集认知、运动及其他非运动特征,采用线性混合效应模型分析纵向变化。
主要发现
- 两个DBS组均显示运动症状显著改善(异动症、开关现象、剂末现象,所有p vs T0 < 0.001),未手术GBA组无此获益。
- 5年时痴呆发生率:DBS-GBA组25.5%、未手术GBA组36.8%、DBS非GBA组10.8%(p < 0.001)。
- 幻觉和泌尿问题在两个GBA组均高于非GBA组(组间p < 0.001至0.02),与DBS无关。
- 按GBA1变异类别或DBS靶点分层,术后3年内未见相关差异。
关键数值与推荐
- 5年痴呆发生率:DBS-GBA-PD 25.5%,nonDBS-GBA-PD 36.8%,DBS-nonGBA-PD 10.8%(p < 0.001)。
- 运动改善(异动症、开关现象、剂末现象)在DBS组均p vs T0 < 0.001。
- 幻觉和泌尿问题组间比较p < 0.001至0.02。
临床怎么用
- GBA1变异帕金森病患者仍可考虑DBS以改善运动症状和生活质量。
- 术前应告知GBA1携带者认知下降风险较高,但该风险与DBS无关。
局限性
- 回顾性设计可能引入选择偏倚和混杂因素。
- 5年数据仅在部分患者中可用,可能存在随访偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Deep brain stimulation (DBS) is an established treatment for Parkinson disease (PD). In patients carrying GBA1 variants (GBA-PD), concerns persist that DBS may accelerate cognitive decline. This study investigated the potential additive effects of GBA1 genotype and DBS on long-term motor and nonmotor outcomes. METHODS: This multicenter retrospective, controlled, Italian study included 3 groups: DBS-treated PD patients either carrying or noncarrying GBA1 variants (DBS-nonGBA-PD and DBS-GBA-PD) and GBA-PD patients who fulfilled DBS criteria but eventually were not operated. As secondary aims, we assessed the clinical outcomes of DBS-GBA-PD stratified by GBA1 variant classes and by different DBS targets. Cognitive, motor, and other nonmotor features were collected at baseline and after 1, 3 and, when available, 5 years. Between-group comparisons used χ2 and Kruskal-Wallis tests with Bonferroni correction. Longitudinal changes were analyzed with linear mixed-effects models. Subgroup analyses were performed by GBA1 variant class and DBS target. RESULTS: A total of 615 participants were included: 430 DBS-nonGBA-PD (age 57.4 ± 7.7 years, 32% female), 109 DBS-GBA-PD (age 53.5 ± 8.4 years, 38% female), and 76 nonDBS-GBA-PD (age 57.7 ± 8.1 years, 37% female). At baseline, groups were largely matched for clinical features. Longitudinally, both DBS groups showed marked motor improvement (dyskinesias, on-off phenomenon, and wearing-off, all p vs T0 < 0.001), a benefit which was absent in nonDBS-GBA-PD. At 5 years, dementia occurred more frequently in DBS-GBA-PD and nonDBS-GBA-PD compared with DBS-nonGBA-PD (25.5% vs 36.8% vs 10.8%, p < 0.001). Hallucinations and urinary problems increased in both GBA-PD groups than nonGBA-PD (p-between <0.001 and 0.02, respectively), regardless of DBS. No relevant differences emerged on stratification for variant classes or DBS targets, up to 3 years postsurgery. DISCUSSION: Despite its retrospective design, this study supports DBS as a valid therapeutic option for GBA-PD, providing prolonged benefits on motor symptoms and quality of life. The accelerated cognitive decline observed in GBA-PD, compared with non-mutated participants, was similarly present in both operated and non-operated groups, suggesting it is driven by the genotype rather than DBS itself. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that DBS does not worsen cognitive function in patients with GBA1-associated PD.
引用
- Avenali M, Artusi CA, Cilia R, et al. Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant. Neurology. 2025. PMID: 41124650. doi:10.1212/WNL.0000000000214036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。